Madrid, 19 (Europa Press)
The Vaccine Alliance, Derrick Sim, General Director of Vaccine Markets and Health Security at Gavi, is in favor of “introducing” measles and rubella vaccine patches to less developed countries, following recent clinical trials of this type of vaccine. After knowing about
“The vaccine patch has the potential to transform immunization, especially in low-income countries where health infrastructure is less developed. With these very encouraging clinical trial results, it is now time for all of us to step up and lead the way.” Now is the right time to bring this technology platform to the market for measles and rubella, and a range of pandemic and endemic vaccines in the future,” Sim explained.
Results announced by Micron Biomedicals earlier this week indicated that the measles and rubella vaccine patch has completed Phase 1/2 clinical trials. These results show for the first time the potential of vaccine patches to safely and effectively deliver vaccines to children.
According to Gavi, needle-less vaccine technology has the potential to transform vaccination and make it accessible to everyone, everywhere. This is especially important in the case of measles and rubella, as high vaccination coverage is needed globally to prevent measles outbreaks and coverage has decreased significantly following the COVID-19 pandemic.
Vaccine ‘microarray’ patches (Vaccine MAPs), also known as microneedle patches, have microscopic projections that are applied to the body like a small bandage, which punctures the outermost layer of skin to deliver the vaccine. penetrates flawlessly.
This new application is expected to be easier to implement than conventional vaccines, “making them suitable for distribution in hard-to-reach settings or for rapid deployment of protective vaccines in future pandemics or epidemics.”
In this regard, Gavi and its partners, WHO, UNICEF, the Bill & Melinda Gates Foundation, PATH, CEPI and the US Department of Defense and Biomedical Advanced Research and Development Authority, are requesting investments to fund the construction facilities. late-stage clinical trials to accelerate their availability.
